Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A decade later, gene discovered by Temple researchers found to be multi-functional

12.02.2003


A gene discovered by Temple University researchers a decade ago has proved to be multi-functional, with the discovery of its important roles in cell differentiation, HIV transcription, and tumorigenesis.



Cdk9 (cyclin-dependent kinases) and cdk10 were originally isolated by Antonio Giordano, M.D., Ph.D., then a researcher in Temple’s Fels Cancer Institute, and his team in 1992. They are members of a family of kinases originally referred to as a PITALRE, which is the name of the amino acids sequence that is similar to all in this kinase family (http://landesbioscience.com/journals/cancerbio/papersinpress/1.4/cbt03040266.html).

"We were screening a human DNA library in order to look for members of this family and we found cdk9, a gene that encodes for a protein that has the size of 43 kilodaltons," says Giordano, now director of the Sbarro Institute for Cancer Research and Molecular Medicine in Temple’s College of Science and Technology (http://www.temple.edu/news_media/hkg696.html).


Over the next 10 years, cdk9 would prove to be a "multi-functional" gene, playing many different roles.

According to Giordano, among the many functions of cdk9 that have been discovered, one of the most interesting is the role of this kinase in cellular differentiation, particularly muscle differentiation.

"In practical terms, when we overexpress this protein, we are able to promote myogenic differentiation by enhancing the myoD function," says Giordano, who also discovered the tumor suppressing gene Rb2/p130. "Our studies demonstrate that in human tissue, cdk9 is a very important player in specialized tissue, such as muscle or lymphoid tissue."

Another important discovery, says Giordano, shows that if cdk9 is inhibited, or blocked, it prevents the promotion of differentiation, suggesting that this kinase plays a central role in controlling muscle differentiation by regulating directly, genes and their products, such as myoD that is specific for muscle.

"Cdk9 is not only involved in this muscle program, but its specific role in muscle differentiation is important in other programs, such as neurons and astrocytes maturation," he adds. "In addition, cdk9 has been found by several researchers to play a clinical role in other important processes such as apoptosis and in the regulation of the HIV protein Tat."

More recently, based on the discovery of cdk9’s role in muscle differentiation, Giordano collaborated with Dr. Michael D. Schneider of the DeBakey Heart Center at the Baylor University College of Medicine, who demonstrated that cdk9 can be used to block life-threatening hypertrophy or enlargement of the heart. Their study was published in the November 2002 issue of Nature Medicine (www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v8/n11/abs/nm778.html).

An immunologic role for cdk9 has also been discovered and was reported this past fall in Oncogene by Giordano in collaboration with Professor Piero Tosi’s group at the University of Siena in Italy. They have shown that it interacts with gp130, the receptor of the Interleukin-6 (IL-6) family of cytokines.

This discovery, says Dr. Michele Maio, Director of the Cancer Bioimmunotherapy Unit of the Centro di Riferimento Oncologico of Aviano in Italy and adjunct professor at Temple, highlights a totally new biologic role of cdk9. "This should allow us to take advantage of IL-6 as therapeutic agents for targeted therapy in selected histotypes of human cancer."

"Cdk9 acts preferentially by controlling processes such as transcription and the balance between differentiation and apoptosis (programmed cell death), suggesting the important role this kinase can have in controlling or blocking important cellular processes. This is important also from a clinical point of view," concludes Giordano, a cancer specialist who is now actively investigating the role of cdk9 in cancer.

Initial clinical trials of a potent inhibitor of cdk9 function, flavopiridol, are now underway at the National Institutes of Health’s National Cancer Institute (NIH/NCI) in collaboration with Aventis Pharmaceutics. Dr. Adrian M. Senderowicz, Principal Investigator and Chief, Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, conducted the first clinical trials with this agent at NIH’s Clinical Center.

Based on his encouraging results, several clinical trials worldwide are now being conducted, with a Phase 3 clinical trial in lung cancer being carried out at different research centers in the world, assuring that the multi-functional legacy of cdk9 continues to grow well into the future.

Preston M. Moretz | EurekAlert!
Further information:
http://www.temple.edu/
http://www.temple.edu/news_media/hkg696.html

More articles from Life Sciences:

nachricht Stiffness matters
22.02.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht Separate brain systems cooperate during learning, study finds
22.02.2018 | Brown University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Stiffness matters

22.02.2018 | Life Sciences

Magnetic field traces gas and dust swirling around supermassive black hole

22.02.2018 | Physics and Astronomy

First evidence of surprising ocean warming around Galápagos corals

22.02.2018 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>